{"id":"nelfinavir-and-omeprazole","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Diarrhea"},{"rate":"10-20","effect":"Nausea"},{"rate":"5-15","effect":"Headache"},{"rate":"5-10","effect":"Rash"},{"rate":"5-10","effect":"Abdominal pain"},{"rate":"5-10","effect":"Hyperglycemia"}]},"_chembl":{"chemblId":"CHEMBL365442","moleculeType":"Small molecule","molecularWeight":"567.80"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nelfinavir inhibits HIV protease, preventing the cleavage of viral polyproteins and blocking viral replication. Omeprazole reduces gastric acid production by inhibiting the proton pump in gastric parietal cells. However, omeprazole can reduce nelfinavir absorption, making this a problematic combination that is generally contraindicated or requires careful management.","oneSentence":"This is a combination of nelfinavir (an HIV protease inhibitor) and omeprazole (a proton pump inhibitor), which work through separate mechanisms to inhibit viral protease and reduce gastric acid respectively.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:56:57.535Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection (nelfinavir component only; omeprazole co-administration is contraindicated or requires dose adjustment)"}]},"trialDetails":[{"nctId":"NCT00251030","phase":"PHASE4","title":"A Study To Estimate The Effect Of Omeprazole On The Pharmacokinetics Of Nelfinavir In Healthy Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2005-11","conditions":"Healthy Volunteers","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Nelfinavir and Omeprazole","genericName":"Nelfinavir and Omeprazole","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a combination of an HIV protease inhibitor (nelfinavir) and a proton pump inhibitor (omeprazole) used together to manage HIV infection and gastric acid-related conditions. Used for HIV-1 infection (nelfinavir component), Gastric acid suppression in HIV patients (omeprazole component).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}